Drug Discovery World

JUNE 26, 2023

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The post Could a monoclonal antibody treat peanut allergy?

Allergies 52

Allergies Antibody In-Vivo In-Vitro 52

Scienmag

FEBRUARY 22, 2021

Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. ” But how do these antibodies function within the tumor? Using innovative in vivo imaging approaches, scientists […]. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.”

In-Vivo 41

In-Vivo Antibody Scientist Allergies 41

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Previously, he held roles as CMO at Trimeris Inc.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

JULY 8, 2021

“We are proud to advance an innovative, first-in-class monoclonal antibody that targets the top of the inflammatory cascade and represents a potentially transformative treatment option for a broad population of patients with severe asthma. .” Amgen (NASDAQ:AMGN) announced that the U.S. Reese, M.D., About Severe Asthma.

Allergies 52

Allergies Trials In-Vivo Medicine 52

The Pharma Data

APRIL 27, 2021

Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent ® and Vaccines. Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% to €1,047 million) and oncology launches. General Medicines core assets grew 4.4%, while GBU sales were down 3.8%.

Sales 52

Sales Vaccination Vaccine Medicine 52